Cagrilintide/semaglutide
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Novo Nordisk · Phase 3 · Completed · Enrollment 300
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| CagriSema Dose 1 | n/r | n/r | n/r | n/r |
| Placebo Dose 1 | n/r | n/r | n/r | n/r |
| CagriSema Dose 2 | n/r | n/r | n/r | n/r |
| Placebo Dose 2 | n/r | n/r | n/r | n/r |
Not shown
- CagriSema Dose 1: endpoint not reported
- Placebo Dose 1: endpoint not reported
- CagriSema Dose 2: endpoint not reported
- Placebo Dose 2: endpoint not reported